Although CDK4/6 inhibitors have a great tendency to bring about positive prognosis of HR+/HER2- breast cancer patients, for other type such as HER2+, TNBC or AR+ breast cancer, the application of CDK4/6 inhibitors still needs further intensive studies. This evidence concerns the gene CDK4 and breast cancer.